Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease.
作者信息
Lee Alexander S, Caldera Freddy
机构信息
Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
出版信息
Crohns Colitis 360. 2020 Oct 27;2(4):otaa086. doi: 10.1093/crocol/otaa086. eCollection 2020 Oct.
Abstract
摘要
相似文献
1
Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease.
Crohns Colitis 360. 2020 Oct 27;2(4):otaa086. doi: 10.1093/crocol/otaa086. eCollection 2020 Oct.
2
The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab.
Crohns Colitis 360. 2020 Oct 27;2(4):otaa082. doi: 10.1093/crocol/otaa082. eCollection 2020 Oct.
3
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
J Gastroenterol Hepatol. 2019 Jul;34(7):1175-1181. doi: 10.1111/jgh.14584. Epub 2019 Jan 16.
4
Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e574-e579. doi: 10.1097/MEG.0000000000002166.
5
Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.
J Clin Pharmacol. 2021 Sep;61(9):1174-1181. doi: 10.1002/jcph.1877. Epub 2021 Jul 14.
6
Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
Transplant Cell Ther. 2024 May;30(5):546.e1-546.e7. doi: 10.1016/j.jtct.2024.03.006. Epub 2024 Mar 7.
7
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.
8
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5.
9
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms.
Drugs Context. 2020 Mar 2;9. doi: 10.7573/dic.2019-10-2. eCollection 2020.
10
Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Dig Dis Sci. 2022 Jun;67(6):2480-2484. doi: 10.1007/s10620-021-07046-7. Epub 2021 May 21.
引用本文的文献
1
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease.
Saudi J Gastroenterol. 2022 Nov 21;29(Suppl 1):S1-S35. doi: 10.4103/sjg.sjg_277_22.
2
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
Clin Transl Gastroenterol. 2022 Apr 1;13(4):e00484. doi: 10.14309/ctg.0000000000000484.
本文引用的文献
1
The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab.
Crohns Colitis 360. 2020 Oct 27;2(4):otaa082. doi: 10.1093/crocol/otaa082. eCollection 2020 Oct.
2
Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.
Inflamm Bowel Dis. 2020 Mar 4;26(4):593-602. doi: 10.1093/ibd/izz164.
3
High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease.
Am J Gastroenterol. 2019 Jul;114(7):1130-1141. doi: 10.14309/ajg.0000000000000289.
4
Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2019 Jan 10;25(2):369-376. doi: 10.1093/ibd/izy243.
5
Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
J Crohns Colitis. 2018 Jul 30;12(8):905-919. doi: 10.1093/ecco-jcc/jjy047.
6
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12.
7
ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27.
8
ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
Am J Gastroenterol. 2017 Feb;112(2):241-258. doi: 10.1038/ajg.2016.537. Epub 2017 Jan 10.
9
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
10
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
Gut. 2015 Jan;64(1):77-83. doi: 10.1136/gutjnl-2014-307127. Epub 2014 Apr 24.
Zotero 插件